

# company announcement

## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 20 January 2014** – On 31 October 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January 2013.

Under the programme initiated 31 October 2013, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 31 October 2013 to 28 January 2014.

Since the announcement as of 13 January 2014, the following transactions have been made under the programme:

|  | Number of<br>shares | Average<br>purchase price | Transaction<br>value, DKK |
|--|---------------------|---------------------------|---------------------------|
| <b>Accumulated, last announcement</b>  | <b>11,228,055</b>   |                           | <b>2,179,165,141</b>      |
| 13 January 2014                        | 250,000             | 212.66                    | 53,165,950                |
| 14 January 2014                        | 245,000             | 210.48                    | 51,568,580                |
| 15 January 2014                        | 245,000             | 211.72                    | 51,870,224                |
| 16 January 2014                        | 245,000             | 210.07                    | 51,466,636                |
| 17 January 2014                        | 245,000             | 209.29                    | 51,275,070                |
| <b>Accumulated under the programme</b> | <b>12,458,055</b>   |                           | <b>2,438,511,600</b>      |

With the transactions stated above, Novo Nordisk owns a total of 105,922,025 treasury shares, corresponding to 3.9% of the share capital. The total amount of shares in the company is 2,750,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14.0 billion during a 12-month period beginning 31 January 2013. As of 17 January 2014, Novo Nordisk has repurchased a total of 70,650,270 B shares equal to a transaction value of DKK 13,626,332,271.

*Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com).*

## Further information

### Media:

|                      |                 |  |
|----------------------|-----------------|--|
| Anne Margrethe Hauge | +45 4442 3450   | <a href="mailto:amhg@novonordisk.com">amhg@novonordisk.com</a> |
| Ken Inchausti (US)   | +1 609 514 8316 | <a href="mailto:kiau@novonordisk.com">kiau@novonordisk.com</a> |

### Investors:

|                         |                 |  |
|-------------------------|-----------------|--|
| Kasper Roseeuw Poulsen  | +45 3079 4303   | <a href="mailto:krop@novonordisk.com">krop@novonordisk.com</a> |
| Frank Daniel Mersebach  | +45 3079 0604   | <a href="mailto:fdni@novonordisk.com">fdni@novonordisk.com</a> |
| Lars Borup Jacobsen     | +45 3075 3479   | <a href="mailto:lbj@novonordisk.com">lbj@novonordisk.com</a>   |
| Daniel Bohsen           | +45 3079 6376   | <a href="mailto:dabo@novonordisk.com">dabo@novonordisk.com</a> |
| Jannick Lindegaard (US) | +1 609 235 8567 | <a href="mailto:jlis@novonordisk.com">jlis@novonordisk.com</a> |